Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Condition(s):Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaLast Updated:November 14, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaLast Updated:November 14, 2023Active, not recruiting
Condition(s):Gastric CancerLast Updated:February 23, 2021Unknown status
Condition(s):Locally Advanced or Metastatic and Unresectable HCCLast Updated:February 6, 2024Completed
Condition(s):Gastric Cancer; GastroEsophageal CancerLast Updated:August 25, 2021Unknown status
Condition(s):Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CarcinomaLast Updated:April 25, 2022Active, not recruiting
Condition(s):Tumor, Solid; Cancer, Metastatic; Neoplasm MalignantLast Updated:November 4, 2022Active, not recruiting
Condition(s):Digestive System CancersLast Updated:October 26, 2023Recruiting
Condition(s):Recurrent and Metastatic Gastric CancerLast Updated:March 7, 2017Unknown status
Condition(s):Osteosarcoma; Pulmonary Metastases; ApatinibLast Updated:November 1, 2023Active, not recruiting
Condition(s):Immunotherapy Gastrict CancerLast Updated:June 18, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.